AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 2 filers reported holding AUDENTES THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $5,631,000 | +239.2% | 94,099 | +59.2% | 0.00% | +200.0% |
| Q3 2019 | $1,660,000 | -24.4% | 59,100 | +1.9% | 0.00% | 0.0% |
| Q2 2019 | $2,196,000 | +41.0% | 58,000 | +45.4% | 0.00% | 0.0% |
| Q1 2019 | $1,557,000 | -66.4% | 39,900 | -81.6% | 0.00% | -66.7% |
| Q4 2018 | $4,633,000 | -82.3% | 217,300 | -67.1% | 0.00% | -82.4% |
| Q3 2018 | $26,141,000 | +45.4% | 660,281 | +40.3% | 0.02% | +30.8% |
| Q2 2018 | $17,976,000 | +77.3% | 470,456 | +39.5% | 0.01% | +85.7% |
| Q1 2018 | $10,138,000 | -28.9% | 337,355 | -26.1% | 0.01% | -30.0% |
| Q4 2017 | $14,257,000 | -16.3% | 456,223 | -24.9% | 0.01% | -23.1% |
| Q3 2017 | $17,024,000 | +38.9% | 607,795 | -5.1% | 0.01% | +44.4% |
| Q2 2017 | $12,256,000 | +47.7% | 640,654 | +31.5% | 0.01% | +28.6% |
| Q1 2017 | $8,299,000 | -14.8% | 487,037 | -8.7% | 0.01% | -12.5% |
| Q4 2016 | $9,743,000 | -3.3% | 533,258 | -5.8% | 0.01% | -11.1% |
| Q3 2016 | $10,078,000 | – | 565,838 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,485,000 | $69,804,000 | 6.41% |
| Versant Venture Management, LLC | 553,916 | $15,559,500,000 | 6.02% |
| Foresite Capital Management III, LLC | 315,331 | $8,858,000 | 3.38% |
| Opaleye Management Inc. | 285,000 | $8,006,000 | 2.90% |
| Redmile Group, LLC | 2,962,655 | $83,221,000 | 2.78% |
| Casdin Capital, LLC | 860,000 | $24,157,400,000 | 2.50% |
| Sofinnova Investments, Inc. | 933,640 | $26,226,000 | 2.37% |
| Eversept Partners, LP | 253,726 | $7,127,163 | 2.21% |
| PFM Health Sciences, LP | 2,315,938 | $65,055,000 | 1.92% |
| Global Endowment Management, LP | 581,488 | $16,334,000 | 1.43% |